Throat Cancer Companies

AstraZeneca's Imfinzi (durvalumab) Phase III trial demonstrates improved overall survival rates when combined with standard chemoradiation for locally advanced head and neck squamous cell carcinoma (HNSCC). This paves the way for potential regulatory approval and wider adoption of immunotherapy in throat cancer treatment.

Merck's Keytruda (pembrolizumab) shows promising results in combination with chemotherapy for recurrent or metastatic HNSCC in a Phase II trial. These findings could lead to expanded treatment options for advanced-stage throat cancer patients.

Precision BioSciences receives FDA Fast Track designation for its PB545, a targeted gene therapy candidate for head and neck cancer, specifically addressing TP53 mutations. This marks a significant step forward in personalized medicine for throat cancer treatment. (Image of Precision BioSciences logo and PB545)

Enobia Therapeutics' INBRX-101 gene therapy candidate demonstrates initial safety and efficacy in phase I/IIa trial for HPV-positive HNSCC. This offers a glimmer of hope for targeting the HPV-driven subset of throat cancers. (Image of Enobia Therapeutics logo and INBRX-101)

List of Throat Cancer Treatment Key Companies in the Market

• Amgen Inc.


• Celgene Corporation


• Eli Lilly and Company


• Engeneic Ltd


• Bristol-Myers Squibb


• Hoffmann-la Roche AG


• Merck & Co., Inc.


• Moderna Inc.


• Novartis


• eTheRNA


• Pfizer Inc.


• Teva Pharmaceutical Industries Ltd